These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 17113983)

  • 1. Prostate cancer risk in testosterone-treated men.
    Raynaud JP
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone deficiency syndrome: treatment and cancer risk.
    Raynaud JP
    J Steroid Biochem Mol Biol; 2009 Mar; 114(1-2):96-105. PubMed ID: 19429438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer in men using testosterone supplementation.
    Gaylis FD; Lin DW; Ignatoff JM; Amling CL; Tutrone RF; Cosgrove DJ
    J Urol; 2005 Aug; 174(2):534-8; discussion 538. PubMed ID: 16006887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
    Kaplan AL; Hu JC
    Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen replacement therapy and prostate safety.
    Morales A
    Eur Urol; 2002 Feb; 41(2):113-20. PubMed ID: 12074396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone replacement therapy and prostate risks: where's the beef?
    Morgentaler A
    Can J Urol; 2006 Feb; 13 Suppl 1():40-3. PubMed ID: 16526980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgens and the ageing male.
    Swerdloff RS; Wang C
    Best Pract Res Clin Endocrinol Metab; 2004 Sep; 18(3):349-62. PubMed ID: 15261842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
    Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
    J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
    Morales A
    BJU Int; 2011 May; 107(9):1369-73. PubMed ID: 21518230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of finasteride on the development of prostate cancer.
    Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
    N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy.
    Klap J; Schmid M; Loughlin KR
    J Urol; 2015 Feb; 193(2):403-13. PubMed ID: 25260832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.
    Lunenfeld B; Saad F; Hoesl CE
    Aging Male; 2005 Jun; 8(2):59-74. PubMed ID: 16096160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.